 |
(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide |
|---|---|
| Trade Name | |
| Orphan Indication | Hemoglobinuria |
| USA Market Approval | USA |
| USA Designation Date | 2017-11-02 00:00:00 |
| Sponsor | Achillion Pharmaceuticals, Inc;300 George Street;New Haven, Connecticut, 06511 |
